Specialty Pharmacy

The study focused on the comparative risk of infection across 7 systemic biologics.

Top news of the day from across the health care landscape.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses how to optimize collaboration among the health care team to prepare for changes that occur throughout the course of a patient's care.

Officials with the FDA have approved extending the indication of Takeda Pharmaceuticals’ teduglutide (Gattex) for injection to pediatric patients age 1 year and older with Short Bowel Syndrome who need additional nutrition or fluids from intravenous feeding.

The convenience of home infusion for these products is very enticing for patients who require them and positioning home infusion pharmacies as partners with prescribers and patients is critical to help support this influx of new therapies.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Dalteparin sodium is the first anticoagulant indicated for pediatric patients approved by the agency.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.

Study explored a novel drug’s efficacy in overcoming ibrutinib-resistant mantle cell lymphoma.

Top news of the day from across the health care landscape.

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia.

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study.

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Top news of the day from across the health care landscape.

Risdiplam showed continued improvements in motor milestones and functions for patients with spinal muscular atrophy.

In 2016, an estimated 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women, according a CDC report.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Procedure uses small incisions and a miniature video camera to reduce the risk of complications from surgery for lung cancer.

Top news of the day from across the health care landscape.

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

From 2018 to 2040, the number of patients who will need chemotherapy each year is estimated to rise from 9.8 million to 15 million.

Promacta (eltrombopag, Novartis) 12.5 mg for oral suspension was distributed nationwide through specialty pharmacies.

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.

Top news of the day from across the health care landscape.

Ramucirumab (Cyramza, Eli Lilly) is approved as a single agent in patients with elevated alpha fetoprotein who have been previously treated with sorafenib.

The pathway is intended to help patients by making more treatment options available through biosimilar and interchangeable products.

This product is a generic version of Genentech's Tarceva.